TAIPEI, November 4, 2025 – REGiMMUNE Limited (“REGiMMUNE” or “the Company”), a clinical-stage biotechnology company dedicated to developing novel therapies for immune-related diseases and cancer, announced that its Board of Directors has approved the appointment of Dr. Steve Yang, current Chief Operating Officer (COO), as the company’s new Chief Executive Officer (CEO), effective November 4, 2025. Dr. Yang is expected to continue advancing REGiMMUNE’s global innovation and development of immune-modulating therapeutics, while leading the strategic execution of the “Japan–Taiwan Biotech Innovation Platform” to establish a solid foundation for REGiMMUNE’s long-term growth and entry into the Taiwan capital market.

“We are confident that Dr. Yang will lead REGiMMUNE into a new phase of growth,” said Mr. Kenzo Kosuda, Chairman of REGiMMUNE. “Since joining the company in May 2024, he has leveraged his strong biomedical background and leadership to accelerate strategic initiatives. He strengthened engagement with investors and partners in Taiwan, facilitated the introduction of innovative immune-modulating therapies, and reinforced REGiMMUNE’s position as an international biotech company ‘Born in Japan, Grow in Taiwan, and Aim at global.’ He will focus on two near-term missions: guiding REGiMMUNE toward listing in the Taiwan capital market and expanding global presence through Japan–Taiwan collaboration and strategic partnerships or acquisitions.”

Dr. Yang holds a Ph.D. in Health Services Organization and Research from the Medical College of Virginia at Virginia Commonwealth University, brings over 20 years of experience in the biomedical sector, specializing in clinical trial design and pharmaco-economics. Prior to joining REGiMMUNE, he founded a clinical research services organization (CRO) and led multiple biopharmaceutical development and commercialization programs at the Industrial Technology Research Institute (ITRI). where he contributed to the development and commercialization of multiple biomedical products.

Commenting on his new role, Dr. Yang said “I am grateful for the Board’s trust. I look forward to working closely with our multinational team to accelerate the development of next-generation immunotherapies, strengthen Japan–Taiwan biotech collaboration, and execute a forward-looking strategy that positions REGiMMUNE as a globally competitive biopharmaceutical company.”

Strategic Priorities Under Dr. Yang’s Leadership

REGiMMUNE will advance the following initiatives in the coming 18–24 months, including:

  • Submission of pre-Phase 3 meeting requests to U.S. and EU regulatory agencies, with a goal to file Phase 3 IND applications in the first quarter of 2026.
  • Launch of the first collaboration under the Japan–Taiwan Biotech Innovation Platform.
  • Preparation for an application to list on Taiwan’s Emerging Stock Board (ESB) in the first half of 2026.

Ends

 

About REGiMMUNE Limited

REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). REGiMMUNE is creating a pipeline of novel product candidates that either enhance Treg activities for immune diseases or suppress Treg activities for cancer.

Corporate Contact

Steve Yang
Chief Executive Officer
REGiMMUNE Limited
+886 2 2555 3377 #511
stevey@regimmune.com

 

 

REGiMMUNE任命楊思聖博士為新任執行長

2025年11月4日，台北 – 瑞格國際生技股份有限公司，一家致力於開發免疫性疾病和癌症新型療法的臨床階段生技公司宣布，董事會正式通過任命現任營運長（COO）楊思聖博士升任執行長（CEO），任期自2025年11月 4日起生效。公司期盼楊博士持續推動免疫新藥的國際開發與創新，並引領「台日生技新藥創新平台」的營運策略，為瑞格進軍台灣資本市場奠定長期成長基礎。

瑞格董事長小須田建三表示：「楊博士自2024年5月加入瑞格以來，憑藉豐富的生醫背景與卓越領導力，積極推動公司策略布局。他不僅深化與台灣投資人及合作夥伴的交流，也協助引進多項創新免疫療法，明確定位瑞格為『源自日本、深耕台灣、放眼全球』的國際級生技新藥公司。未來他將肩負兩大任務：一是帶領公司進入台灣資本市場；二是透過台日產業合作與併購，持續擴展全球市場。我們深信他將為公司帶來新的成長動能。」

楊博士擁有美國維吉尼亞醫學院醫療管理博士學位，具備超過20年生醫產業經驗，專長涵蓋臨床試驗設計、藥物開發與健康經濟研究。在加入瑞格之前，他曾創辦臨床研究服務公司（CRO），並於工業技術研究院（ITRI）參與多項生醫產品研發與商業化推動工作。

談及新職務，楊博士表示：「非常感謝董事會的信任。我期待與瑞格跨國團隊攜手，持續推進免疫新藥開發，強化台日生技創新合作，並以務實且具前瞻性的策略，將瑞格打造為具全球競爭力的生技新藥公司。」

未來發展重點

瑞格在楊博士帶領下，近期將推動以下重要計劃：

  • 向美國與歐盟法規單位申請臨床三期前會議，預計於2026年第一季提交正式試驗申請。
  • 由美國一所頂尖醫學院的權威教授擔任主持人的臨床二期試驗，將於明年第一季在美國血液學年會（ASH）上，首次揭示 RGI-2001 於新適應症領域的臨床潛力，預期將大幅提升產品價值與商業發展前景。
  • 啟動「台日生技新藥創新平台」首件合作案。
  • 計畫於2026年上半年申請登錄台灣興櫃市場。

本文結束

 

關於瑞格

瑞格起源於日本理化學研究所（RIKEN）頂尖免疫研究團隊，其核心科學奠基於2025年諾貝爾醫學獎得主坂口志文教授對調節性T細胞（Treg）免疫機制的開創性發現。

公司主力產品 RGI-2001 為全球首個可活化Treg細胞的小分子藥物，用於預防血癌患者造血幹細胞移植後的急性排斥反應。該藥物已於美國哈佛醫學院領導的臨床二期試驗中展現卓越療效，並將於美歐展開三期臨床試驗。

此外，瑞格的蛋白質藥物研發團隊已開發多項新型抗體，能調控腫瘤微環境中的Treg細胞，預期可顯著提升現有免疫檢查點抑制劑（如anti-PD-1）的治療效果，部分候選抗體已進入臨床前開發
階段。

自2018年於台灣設立營運總部以來，瑞格善用台灣豐富的生技研發資源，積極推動國際合作與商業開發，未來將持續以台灣為樞紐，將日本先進醫藥技術導入全球市場，造福重症患者，並為股東創造長期價值。

 

媒體聯絡人

楊思聖 (Steve Yang)
執行長 (CEO)
瑞格國際生技股份有限公司
+886 2 2555 3377 #511
stevey@regimmune.com